A biologic without guidelines: the YODA project and the future of bone morphogenetic protein-2 research
Authors:
- Eugene J. CarrageeECEugene J. Carragee
- Ray M. BakerRBRay M. Baker
- Edward C. BenzelEBEdward C. Benzel
- Stanley J. BigosSBStanley J. Bigos
- Ivan ChengICIvan Cheng
- Terry P. CorbinTCTerry P. Corbin
- Richard A. DeyoRDRichard A. Deyo
- Eric L. HurwitzEHEric L. Hurwitz
- Jeffrey G. JarvikJJJeffrey G. Jarvik
- James D. KangJKJames D. Kang
- Jon D. LurieJLJon D. Lurie
- Thomas E. MrozTMThomas E. Mroz
- 1 October 2012
- journal article
- editorial
- Published by Elsevier in The Spine Journal
- Vol. 12 (10) , 877-880
Abstract
No abstract availableFunding Information
- Robert Wood Johnson Foundation
- National Institutes of Health
This publication has 13 references indexed in Scilit:
- Commentary: Despite reports of catastrophic complications, why recombinant human bone morphogenetic protein-2 should be available for use in anterior cervical spine surgeryThe Spine Journal, 2012
- Carragee et al respondThe Spine Journal, 2011
- Reply to “A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned”The Spine Journal, 2011
- Science pleaseThe Spine Journal, 2011
- Authors and editors combined response to Zdeblick letter (revised 28 June 2011)The Spine Journal, 2011
- A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learnedThe Spine Journal, 2011
- A challenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factorsThe Spine Journal, 2011
- Pros, cons, and costs of INFUSE in spinal surgerySurgical Neurology International, 2011
- Complications Related to Osteobiologics Use in Spine SurgerySpine, 2010
- The ABCs of BMPsOrthopaedic Nursing, 2005